Clinical applications of radiolabeled monoclonal antibodies for cancer diagnosis and therapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In recent years, considerable experience has been accrued through the clinical applications of radiolabeled monoclonal antibodies in the diagnosis and therapy of malignant diseases. While radioimmunoscintigraphy has established its role in nuclear medicine practice, radioimmunotherapy has thus far gained limited acceptance mainly due to the low amount of radioactivity that can be targeted to the tumor and to the myelotoxicity which is typically the dose limiting factor. Remarkable high therapeutic response rates have been obtained for tumors that are refractory to other therapies through the use oflocoregional administration that allows the delivery of higher radiation doses to produce cytotoxic effects. New strategies based on pretargeting techniques have shown that, unlike directly labeled antibodies, higher doses of radioactivity can be administered systemically without associated bone marrow toxicity. Pilot studies in patients with high grade gliomas, in progression after conventional treatments, have shown that this approach interferes with the progression of tumors and produces tumor regression.

Original languageEnglish
Pages (from-to)146-161
Number of pages16
JournalMinerva Biotecnologica
Volume10
Issue number4
Publication statusPublished - 1998

Fingerprint

Monoclonal antibodies
Tumors
Monoclonal Antibodies
Radioactivity
Dosimetry
Neoplasms
Radioimmunodetection
Radioimmunotherapy
Nuclear medicine
Nuclear Medicine
Therapeutics
Antibodies
Glioma
Refractory materials
Toxicity
Bone
Bone Marrow
Radiation

Keywords

  • Monoclonal antibodies
  • Neoplasms
  • Radioimmunodetection
  • Radioimmunotherapy
  • Tumor pretargeting

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering

Cite this

@article{bba698eed941497fa49673c851f99e9d,
title = "Clinical applications of radiolabeled monoclonal antibodies for cancer diagnosis and therapy",
abstract = "In recent years, considerable experience has been accrued through the clinical applications of radiolabeled monoclonal antibodies in the diagnosis and therapy of malignant diseases. While radioimmunoscintigraphy has established its role in nuclear medicine practice, radioimmunotherapy has thus far gained limited acceptance mainly due to the low amount of radioactivity that can be targeted to the tumor and to the myelotoxicity which is typically the dose limiting factor. Remarkable high therapeutic response rates have been obtained for tumors that are refractory to other therapies through the use oflocoregional administration that allows the delivery of higher radiation doses to produce cytotoxic effects. New strategies based on pretargeting techniques have shown that, unlike directly labeled antibodies, higher doses of radioactivity can be administered systemically without associated bone marrow toxicity. Pilot studies in patients with high grade gliomas, in progression after conventional treatments, have shown that this approach interferes with the progression of tumors and produces tumor regression.",
keywords = "Monoclonal antibodies, Neoplasms, Radioimmunodetection, Radioimmunotherapy, Tumor pretargeting",
author = "Giovanni Paganelli and Marco Chinol",
year = "1998",
language = "English",
volume = "10",
pages = "146--161",
journal = "Minerva Biotecnologica",
issn = "1120-4826",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Clinical applications of radiolabeled monoclonal antibodies for cancer diagnosis and therapy

AU - Paganelli, Giovanni

AU - Chinol, Marco

PY - 1998

Y1 - 1998

N2 - In recent years, considerable experience has been accrued through the clinical applications of radiolabeled monoclonal antibodies in the diagnosis and therapy of malignant diseases. While radioimmunoscintigraphy has established its role in nuclear medicine practice, radioimmunotherapy has thus far gained limited acceptance mainly due to the low amount of radioactivity that can be targeted to the tumor and to the myelotoxicity which is typically the dose limiting factor. Remarkable high therapeutic response rates have been obtained for tumors that are refractory to other therapies through the use oflocoregional administration that allows the delivery of higher radiation doses to produce cytotoxic effects. New strategies based on pretargeting techniques have shown that, unlike directly labeled antibodies, higher doses of radioactivity can be administered systemically without associated bone marrow toxicity. Pilot studies in patients with high grade gliomas, in progression after conventional treatments, have shown that this approach interferes with the progression of tumors and produces tumor regression.

AB - In recent years, considerable experience has been accrued through the clinical applications of radiolabeled monoclonal antibodies in the diagnosis and therapy of malignant diseases. While radioimmunoscintigraphy has established its role in nuclear medicine practice, radioimmunotherapy has thus far gained limited acceptance mainly due to the low amount of radioactivity that can be targeted to the tumor and to the myelotoxicity which is typically the dose limiting factor. Remarkable high therapeutic response rates have been obtained for tumors that are refractory to other therapies through the use oflocoregional administration that allows the delivery of higher radiation doses to produce cytotoxic effects. New strategies based on pretargeting techniques have shown that, unlike directly labeled antibodies, higher doses of radioactivity can be administered systemically without associated bone marrow toxicity. Pilot studies in patients with high grade gliomas, in progression after conventional treatments, have shown that this approach interferes with the progression of tumors and produces tumor regression.

KW - Monoclonal antibodies

KW - Neoplasms

KW - Radioimmunodetection

KW - Radioimmunotherapy

KW - Tumor pretargeting

UR - http://www.scopus.com/inward/record.url?scp=0032420803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032420803&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032420803

VL - 10

SP - 146

EP - 161

JO - Minerva Biotecnologica

JF - Minerva Biotecnologica

SN - 1120-4826

IS - 4

ER -